MentalHealthDaily

Treatment-Resistant Depression in Pakistan: 34% TRD, 86% Polypharmacy

by GLOOM

MHD featured image for treatment-resistant depression, polypharmacy, and CYP2C19 findings in Pakistan.

A 2026 DIVERGE analysis of 3,677 antidepressant-exposed patients with major depressive disorder in Pakistan classified 34% as treatment resistant, while 86% received psychotropic polypharmacy and only 6% received psychotherapy.1 The CYP2C19 signal is real enough to study prospectively, but the main treatment-system finding is medication stacking in a setting where psychological care was rare. Research …

Pharmacogenomics (PGx) for Depression: Genetic Analysis to Amplify Antidepressant Efficacy? (2023 Review)

by GLOOM

Depression, a leading cause of disability globally, often presents challenges in treatment due to the variability in individual responses to antidepressants. Pharmacogenomic (PGx) testing, an approach aligning treatment with genetic makeup, promises to tailor depression therapy more effectively. Highlights: Major Depressive Disorder (MDD) impacts a significant portion of the global population, with traditional treatments often …